These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 7981080)

  • 1. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
    Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
    Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
    Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
    Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
    Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
    J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
    Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
    J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
    Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
    J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
    Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
    Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen.
    Dittadi R; Biganzoli E; Boracchi P; Salbe C; Mione R; Gatti C; Gion M
    Int J Biol Markers; 1998; 13(1):30-41. PubMed ID: 9681297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
    Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
    Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
    Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
    Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
    Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
    J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
    Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
    Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.